Evidence map›Paper›PMID 32270295›Full record

ReviewRheumatology international2020

Eosinophilic granulomatosis with polyangiitis presenting with myositis: case based review.

Sahil Koppikar, Ghaydaa Al-Dabie, Dana Jerome, Ophir Vinik

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Hypereosinophilic Disorders.The journal of allergy and clinical immunology. In practice · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sahil KoppikarDivision of Rheumatology, University of Toronto, Toronto, ON, Canada. Sahil.Koppikar@wchospital.ca.ORCID http://orcid.org/0000-0003-2467-4723
Ghaydaa Al-DabieDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0328-4489
Dana JeromeDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.
Ophir VinikDivision of Rheumatology, University of Toronto, Toronto, ON, Canada.
University of Toronto · CASt. Michael's Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophilic granulomatosis with polyangitis (EGPA) is a systemic necrotizing small-vessel vasculitis that presents heterogeneously as a multi-organ disease. EGPA evolves through three phases: (1) prodromic phase with asthma, atopy and sinusitis, (2) eosinophilic phase characterized by peripheral eosinophilia and eosinophilic infiltration without necrosis, and (3) vasculitic phase involving organ damage. EGPA often presents with asthma, mononeuritis multiplex, lung infiltrates, sinusitis and constitutional symptoms. Although myalgias are common, EGPA rarely presents with true weakness with elevated creatinine kinase (CK). We describe a rare case of a patient presenting with eosinophilic myositis, who subsequently developed fulminant EGPA. The patient's diagnosis was supported by an initial clinical presentation of weakness and elevated CK, followed by fleeting pulmonary infiltrates and mononeuritis multiplex, peripheral eosinophilia, and strongly positive myeloperoxidase anti-cytoplasmic antibody (MPO-ANCA). Muscle biopsy revealed eosinophilic myositis. The patient responded well to high-dose glucocorticoids and cyclophosphamide with improved symptoms and biochemical markers. Based on our literature review, there are only seven similar cases reported of EGPA presenting with myositis and confirmatory muscle biopsies. There is significant heterogeneity in their clinical findings, histopathology and treatments that were used. Our case report and literature review highlights the importance of recognizing myositis as an initial presenting symptom of EGPA, providing an opportunity for early diagnosis and treatment to reduce risk of further disease progression and morbidity.

Indexed as

Aged, 80 and overAntibodies, Antineutrophil CytoplasmicAntirheumatic AgentsChurg-Strauss SyndromeCyclophosphamideEosinophiliaFemaleGlucocorticoidsHumansMononeuropathiesMyositisPeroxidaseTreatment OutcomeAntibodies, Antineutrophil CytoplasmicAntirheumatic AgentsCyclophosphamideGlucocorticoidsPeroxidaseANCA vasculitisEosinophilic granulomatosis with polyangiitis (EGPA)Eosinophilic myositisMPO vasculitisMyositis

Identifiers

PMID32270295
OpenAlexW3015728402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.